Yuanyi Biopharma Appoints CGT Veteran Tom Farrell as President to Accelerate Global Oncology Pipeline

Dec 03, 2024 08:17 CST Updated 08:17

Oricell Therapeutics

Developer of Tumor Immunocyte Products

2024Year12Month2Date, Oricell Therapeutics officially announced the appointmentTom FarrellAs the group president, aiming to further accelerate the development process in the field of global tumor immunotherapy.TomInCGTWith over twenty years of extensive experience in the field, covering fromCMCTo the full range of knowledge in clinical operations, his professional career can even be traced back toCAR-TThe Exploratory Period Before the Advent of the Therapy (2006Year). As two successful cell therapy companies listed on NASDAQ ——Artiva Biotherapeutics (NASDAQ:ARTV) AndBellicum Pharmaceuticals

(NASDAQ:BLCM) The foundingCEO, TomNot only successfully led the team to develop cell products with global innovative advantages, but also in financing andBDhas made remarkable achievements in this aspect.

Regarding this collaboration, Tom Farrell said: "I am very pleased to become a part of Oricell Therapeutics and have the opportunity to lead the team in accelerating the global development process of our products. I am particularly optimistic about the unique and innovative platform technologies that Oricell has developed over the years, which effectively address some key challenges in cell therapy products while focusing on enhancing safety and efficacy. Through meticulous target screening and optimization, combined with multi-target logic gate construction, multi-mechanism Ori structure design, and highly efficient CMC processes, the Oricell team has significantly improved T-cell performance, enhanced tumor infiltration and resistance to exhaustion, thereby comprehensively improving the safety and efficacy of CAR-T drugs. Oricell Therapeutics’ pipeline is rich and innovative, and its core products have already been validated in early exploratory clinical trials (IIT) and registrational clinical trials, fully demonstrating the tremendous development potential of these products. I am very much looking forward to working closely with the team to collectively achieve future clinical development goals and reach strategic cooperation milestones."

Yang Huanfeng, Co-founder and CEO of Qrigincell Therapeutics, extended a warm welcome to Tom: "Both the company's board of directors and our team are highly anticipating collaborating with Tom to accelerate the clinical development process of our GPRC5D-targeted OriCAR-017 Phase Ib/2a and other products in the United States. Together, we will transform our vision into reality and bring innovative and effective cell therapies to patients."

About Oricell Therapeutics

Qrigincell Therapeutics is a clinical-stage biotechnology company dedicated to becoming an innovation-driven global leader in cancer immunotherapy. It currently focuses on developing novel cell therapies to address unmet medical needs in the fields of oncology and immunology worldwide.Through its self-innovated Ori®Ab antibody screening and engineering platform, Ori®CAR structure platform, and expertise accumulated in the CMC field, Qrigincell Therapeutics has developed multiple product pipelines for treating hematologic malignancies and solid tumors. These have demonstrated good safety and efficacy in exploratory clinical studies. Relevant clinical research data were published at international conferences such as the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH, as well as in the international academic journal *The Lancet Haematology*.

E.N.D

Previous article recommendations:

RegeneCyte™ Cord Blood Stem Cell Therapy Receives FDA Approval for Market Launch

A Cell Therapy Company in China Goes Public in Hong Kong

Immunotech Successfully Raised HKD 2.3 Billion

Four Departments Including the National Health Commission and the Ministry of Commerce Issue Document: Nine Provinces/Cities to Pilot Allowing Wholly Foreign-Owned Hospitals, but with Restrictions on Experimental Treatments like Tumor Cell Therapy

The First Stem Cell Therapy Adverse Reaction Liability Insurance Launched in Sichuan

OriCell Therapeutics and Hanshin Biotech Reach Strategic Cooperation to Jointly Advance the Innovation and Application of Nucleic Acid Drugs

Huaxi Licheng Hospital Officially Opens, Featuring "Stem Cell Therapy" and Other Specialized Treatment Models

$1.5 Billion! Roche Acquires a Cell and Gene Therapy Company

Shanghai Releases "Science and Technology Innovation Action Plan" Cell and Gene Therapy Special Project Approval Notice

Phase I Clinical Data of iPSC-Derived CAR-T Cell Therapy for Lupus Erythematosus Released

George Church's Team Develops mRNA Anti-Aging Therapy, Reversing Skin Aging

Focusing on the Cell and Gene Therapy Field, a Research and Production Base in China Completed and Put into Use

CSPC Group Initiates Phase I Clinical Trial of CAR-T Cell Therapy for Systemic Lupus Erythematosus

Ministry of Commerce: Proactively lay out key industries such as cell and gene therapy, and support Suzhou Industrial Park in piloting open innovation across the entire biopharmaceutical industry chain.

Breaking Through Solid Tumor Limitations: Latest 'Nature' Publishes CAR-T Clinical Trial Results for Deadly Brain Tumors

CDE Releases "Technical Guideline for Clinical Pharmacology Studies of Cell Therapy Products (Trial)"

A Biotech Company in Guangdong Officially Opens, Focusing on Cell and Gene Therapy Fields

Breaking AAV Payload Limits, "Science" Publishes Research on StitchR™ RNA Assembly Technology and Its Application in Treating Muscular Dystrophy

The World's First In Vivo CAR Gene Therapy Approved for Phase I Clinical Trial Completes First Patient Dosing

Total investment of approximately 3 billion yuan, with a construction area of 100,000 square meters, a domestic cell therapy drug research and development and production base has officially started construction.

The World's First TIL Cell Therapy Generated 640 Million in Revenue in Six Months, Expected to Exceed 1.1 Billion for the Year

The World’s First Stem Cell Therapy for Type 1 Diabetes Advances to Phase 3 Clinical Trials

Acquisition Price Approximately 187 Million Yuan: Northeast Pharmaceutical to Officially Acquire 70% Equity in a Cell Therapy Company in China

Official Announcement! Stem Cell Exosomes Not Managed as Medical Devices

World's First! Bioray Biotech's Non-Viral Targeted Integration PD1-CAR-T Therapy for Lupus Erythematosus Approved for Clinical Trials in China

Shanghai Releases Three-Year Action Plan, Continuously Supporting Innovation and R&D in Frontier Areas Such as Cell and Gene Therapy, Nucleic Acid Drugs, and Brain-Computer Interfaces (with Policy Interpretation)

Disclaimer: The content is sourced from the official channels of Oricell Therapeutics Holdings Limited. This article aims to share knowledge, all content is for reference only and does not constitute any recommendations.